PURPOSE: Over the last several years, donor lymphocyte infusions have become the standard approach for patients with chronic myelogenous leukemia (CML) who relapse after allogeneic stem cell transplantation (SCT). Recent reports indicate that imatinib mesylate (Gleevec) can induce remissions in these patients as well. Less is known about the extent and durability of these responses. EXPERIMENTAL DESIGN: We studied 15 patients treated with imatinib for recurrent CML after SCT, 10 patients with stable phase CML (SP-CML), 1 with accelerated phase (AP-CML), and 4 with blast phase (BP-CML). The dose of imatinib was 600 mg (n = 10) or 400 mg (n = 5) daily. Patients were followed for hematological, cytogenetic, and molecular response. A susbset of responders was followed for changes in donor-derived hematopoietic chimerism. RESULTS: Of the 10 patients with SP-CML, all achieved a hematological response. Within 3 months, five of these patients had achieved a complete cytogenetic response (CCR). By six months, 9 of 10 patients had achieved CCR. The BCR-ABL transcript could not be detected by reverse transcription-PCR in 7 of these 9 patients. Patients who achieved CCR showed evidence of conversion to complete donor chimerism. No patient developed graft-versus-host disease. With a median follow up of 25 months, all patients are alive and 9 of 10 patients remain in CCR. Only one of the 5 patients with AP/BP-CML achieved a complete cytogenetic response. CONCLUSIONS: We find that imatinib is well tolerated in patients with SP-CML who relapse after SCT. Responses were rapid, durable, and associated with conversion to full donor chimerism without graft-versus-host disease. Imantinib was far less effective in patients who relapsed with AP/BP-CML. Imatinib should be evaluated as either an alternative or as an adjunct to donor lymphocyte infusions for patients with SP-CML who relapse after SCT.
PURPOSE: Over the last several years, donor lymphocyte infusions have become the standard approach for patients with chronic myelogenous leukemia (CML) who relapse after allogeneic stem cell transplantation (SCT). Recent reports indicate that imatinib mesylate (Gleevec) can induce remissions in these patients as well. Less is known about the extent and durability of these responses. EXPERIMENTAL DESIGN: We studied 15 patients treated with imatinib for recurrent CML after SCT, 10 patients with stable phase CML (SP-CML), 1 with accelerated phase (AP-CML), and 4 with blast phase (BP-CML). The dose of imatinib was 600 mg (n = 10) or 400 mg (n = 5) daily. Patients were followed for hematological, cytogenetic, and molecular response. A susbset of responders was followed for changes in donor-derived hematopoietic chimerism. RESULTS: Of the 10 patients with SP-CML, all achieved a hematological response. Within 3 months, five of these patients had achieved a complete cytogenetic response (CCR). By six months, 9 of 10 patients had achieved CCR. The BCR-ABL transcript could not be detected by reverse transcription-PCR in 7 of these 9 patients. Patients who achieved CCR showed evidence of conversion to complete donor chimerism. No patient developed graft-versus-host disease. With a median follow up of 25 months, all patients are alive and 9 of 10 patients remain in CCR. Only one of the 5 patients with AP/BP-CML achieved a complete cytogenetic response. CONCLUSIONS: We find that imatinib is well tolerated in patients with SP-CML who relapse after SCT. Responses were rapid, durable, and associated with conversion to full donor chimerism without graft-versus-host disease. Imantinib was far less effective in patients who relapsed with AP/BP-CML. Imatinib should be evaluated as either an alternative or as an adjunct to donor lymphocyte infusions for patients with SP-CML who relapse after SCT.
Authors: K Hirschbuehl; A Rank; T Pfeiffer; H R Slawik; G Schlimok; H J Kolb; Ch Schmid Journal: Bone Marrow Transplant Date: 2015-01-12 Impact factor: 5.483
Authors: Vivian G Oehler; Ted Gooley; David S Snyder; Laura Johnston; Allen Lin; Carrie C Cummings; Su Chu; Ravi Bhatia; Stephen J Forman; Robert S Negrin; Frederick R Appelbaum; Jerald P Radich Journal: Blood Date: 2006-10-24 Impact factor: 22.113
Authors: Joshua F Zeidner; Marianna Zahurak; Gary L Rosner; Christopher D Gocke; Richard J Jones; B Douglas Smith Journal: Leuk Lymphoma Date: 2014-06-16
Authors: Anne M Dickinson; Kim F Pearce; Jean Norden; Stephen G O'Brien; Ernst Holler; Heike Bickeböller; Yesilda Balavarca; Vanderson Rocha; Hans-Jochem Kolb; Ilona Hromadnikova; Petr Sedlacek; Dietger Niederwieser; Ronald Brand; Tapani Ruutu; Jane Apperley; Richard Szydlo; Els Goulmy; Wolfgang Siegert; Theo de Witte; Alois Gratwohl Journal: Haematologica Date: 2010-03-19 Impact factor: 9.941
Authors: Sarah Schmidt; Ying Liu; Zhen-Huan Hu; Kirsten M Williams; Hillard M Lazarus; Ravi Vij; Mohamed A Kharfan-Dabaja; Guillermo Ortí; Peter H Wiernik; Daniel Weisdorf; Rammurti T Kamble; Roger Herzig; Baldeep Wirk; Jan Cerny; Ulrike Bacher; Naeem A Chaudhri; Sunita Nathan; Nosha Farhadfar; Mahmoud Aljurf; Usama Gergis; Jeffrey Szer; Sachiko Seo; Jack W Hsu; Richard F Olsson; Dipnarine Maharaj; Biju George; Gerhard C Hildebrandt; Vaibhav Agrawal; Taiga Nishihori; Hisham Abdel-Azim; Edwin Alyea; Uday Popat; Ronald Sobecks; Bart L Scott; Jennifer Holter Chakrabarty; Wael Saber Journal: Biol Blood Marrow Transplant Date: 2020-02-14 Impact factor: 5.742